Navigation Links
AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Date:6/10/2009

QUEBEC CITY, June 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the opening of an extended study in the Phase 3 program with cetrorelix pamoate for the treatment of benign prostatic hyperplasia (BPH), a benign enlargement of the prostate, affecting more than 20 million men in the U.S. alone. Sanofi-aventis U.S. LLC entered into a previously announced agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

As a result of this collaboration between sanofi-aventis U.S. and AEterna Zentaris, patients completing two years of therapy in the North American trial of cetrorelix, NCT00449150, will be eligible to continue with cetrorelix treatment, according to treatment regimen of the ongoing Phase 3 study, until the end of 2011. Patients entering this extension study will be followed-up for safety, International Prostate Symptom Score (IPSS) and quality of life during the extended treatment, providing follow-up data on cetrorelix for up to 5 years.

Juergen Engel, Ph.D., President and CEO of AEterna Zentaris commented, "We have been pleased with the decision of patients and their physicians to continue into this extended period of open-label treatment follow-up, sponsored by our partner sanofi-aventis U.S. We are confident that patients and their physicians will continue into this extension, as the continuation rate of patients into the open-label part of the study remains at over 90% of those eligible to continue at week 52 and compares favorably with those reported by others.(1) We look forward to presenting the data from the double-blind portion of the study in the next quarter."

About the Phase 3 Program with Cetrorelix in BPH

Cetrorel
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
2. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
3. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
4. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
5. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
6. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
7. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
8. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
9. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
10. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
11. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 In contrast to traditional ... with various colors, Valoya uses proprietary LED technology to ... best possible uniformity which is critical in low proximity ... spectral accuracy throughout its lifetime which is up to ... , "The investment cost was clearly higher when ...
(Date:12/19/2014)... 2014 With only 2 weeks left ... on Sartorius Biohit products . The product specials include ... Electronic Pipette Trade-in Program, and free pipette tips. , ... around the world. They are ideal for lab technicians ... ,     Full volume range of 0.1 uL ...
(Date:12/19/2014)... -- Egenix, Inc. is pleased to announce that Lionel ... to succeed Donald Fresne ; Mr. Fresne has also ... member of the Board.  In recognition of the many contributions ... almost twenty years, the Board designated Mr. Fresne as Chairman ... a Search Committee to find a suitable replacement with Biotech ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... New campus will accommodate planned company growth , ... at General Robotics and was struck by the entrepreneurial ... time clock, still found in many businesses today. Twenty-two ... and is expanding his recently renamed healthcare software company ...
... from the U.S. Environmental Protection Agency , ... investigate what happens if infectious prion proteins - ... mad cow disease - enter wastewater treatment plants. ... and ,a href="http://www.soils.wisc.edu/soils/people/faculty/pedersen.htm" target="blank">Joel Pedersen currently investigating ...
... , which provides molecular cloning products to genetics researchers, has ... clone genes that may solve a persistent problem in ... they analyze genes using standard methods, explained Ron Godiska, a ... of DNA that react poorly to standard cloning techniques, which ...
Cached Biology Technology:API Software continues expansion 2Researchers to study fate of prions in wastewater 2Lucigen aims to fill holes in genetic maps with new technique 2
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... sclerosis is caused by a combination of genetic and ... to be such external influences. According to scientists from ... it is apparently not harmful bacteria that trigger ... intestinal flora, which every human being needs for digestion. ...
... such as microscopy play a central role. The technique ... method in this field that promises many benefits. This ... Committee of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) ... in the Life Sciences" initiative, to equip nine universities ...
... PROVO, Utah, Oct. 27, 2011 Nu Skin Enterprises, ... announce that it has executed a letter of intent ... in Madison, Wisconsin for $11,662,500. The letter of intent ... of LifeGen, including its tissue bank, proprietary gene expression ...
Cached Biology News:Natural intestinal flora involved in the emergence of multiple sclerosis 2Natural intestinal flora involved in the emergence of multiple sclerosis 3On the trail of biomarkers and signalling substances with major instrumentation 2Nu Skin Enterprises Enters Into a Letter of Intent to Acquire LifeGen Technologies 2Nu Skin Enterprises Enters Into a Letter of Intent to Acquire LifeGen Technologies 3Nu Skin Enterprises Enters Into a Letter of Intent to Acquire LifeGen Technologies 4
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
... Pyruvate Kinase. This product is ... from other mammalian species but has ... Gives a single precipitin line against ... been shown to react with all ...
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... Shimadzu Phoretix 2D, Expression and Evolution supports ... comparative gel analysis studies in determining differential ... on component Oracle data base ... 2 client software). Supports advanced ...
Biology Products: